Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Grid Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Grid Therapeutics

Grid Therapeutics

Series B

Grid Therapeutics, a biotech firm, pioneers in developing human-derived targeted immunotherapy for cancer.

HQ
Durham, NC, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Grid Therapeutics, founded by Edward F. Patz, Jr. MD and his team at Duke University Medical Center, is a clinical-stage biotechnology company based in Durham, North Carolina. The company's core mission is to develop innovative, human-derived targeted immunotherapies for cancer. Their lead product, "GT103," is an antibody discovered in early-stage lung cancer patients, isolated using advanced molecular genomic techniques. Grid Therapeutics focuses on harnessing the power of the human immune system to create safer and more effective cancer treatments.

Notable figures affiliated with Grid Therapeutics include its founder, Edward F. Patz, Jr., who is a prominent scientist at Duke University Medical Center. The company has attracted significant attention and investment due to its groundbreaking approach to cancer therapy. Key achievements include the development and clinical progression of GT103, which represents a novel class of tumor-specific therapeutic antibodies. Grid Therapeutics' impact lies in its potential to revolutionize cancer treatment by offering targeted, patient-derived immunotherapies that promise improved outcomes and reduced side effects for cancer patients.

Grid Therapeutics - Similar Companies

G1 Therapeutics logo

G1 Therapeutics

g1therapeutics.com

GO Therapeutics logo

GO Therapeutics

gotherapeutics.com

Grit Bio logo

Grit Bio

Gritstone bio logo

Gritstone bio

gritstonebio.com

Immune-Onc Therapeutics logo

Immune-Onc Therapeutics

immuneonc.com

Eugit Therapeutics logo

Eugit Therapeutics

PIC Therapeutics logo

PIC Therapeutics

Checkpoint Therapeutics logo

Checkpoint Therapeutics

checkpointtx.com

Geneos Therapeutics logo

Geneos Therapeutics

geneostx.com

Window Therapeutics logo

Window Therapeutics

windowtx.com

TumorGen logo

TumorGen

tumorgen.net

Gitr logo

Gitr

Advanced Cancer Therapeutics logo

Advanced Cancer Therapeutics

Indapta Therapeutics logo

Indapta Therapeutics

indapta.com

OncoResponse logo

OncoResponse

Grid Therapeutics - Quick Facts

Who are Grid Therapeutics' competitors?

Companies similar to Grid Therapeutics include G1 Therapeutics, GO Therapeutics, Grit Bio and Gritstone bio.

When was Grid Therapeutics founded?

Grid Therapeutics was founded in 2014.

Where is Grid Therapeutics' headquarters located?

Grid Therapeutics' headquarters is located in Durham, NC, US.

When was Grid Therapeutics' last funding round?

Grid Therapeutics' most recent funding round was for $5M (USD) in March 2018.

How much has Grid Therapeutics raised to-date?

As of Mar 27, 2018, Grid Therapeutics has raised a total of $5M (USD).

How many employees does Grid Therapeutics have?

Grid Therapeutics has 10 employees as of Feb 5, 2024.

Grid Therapeutics - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Main Product
  • Cancer Therapies
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified